New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-49
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626-33
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634-41
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-26
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-16
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-7
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47
   PubMed Web of Science ®Google Scholar
• Choi WW, Weisenburger DD, Greiner TC, A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-502
   PubMed Web of Science ®Google Scholar
• Seki R, Ohshima K, Fujisaki T, Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2009;100:1842-7
   PubMed Web of Science ®Google Scholar
• Gu H, Tulpule A, Berman N, Phase II trial of pegylated liposomal doxorubicin (PLD), Rituxan, cyclophosphamide, vincristine, and prednisone in aggressive B-cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26(Suppl): abstract 8563
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Czuczman MS, Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069-76
   PubMed Web of Science ®Google Scholar
• Ribrag V, Gisselbrecht C, Haioun C, Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer 2009;115:4540-6
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4952-7
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, LaPlant B, Habermann T, A phase I/II trial of lenalidomide and RCHOP (R2CHOP) in patients with newly diagnosed diffuse large B-cell (DLBCL) and follicular grade 3 lymphoma. Blood 2009;114: abstract 1669
   Google Scholar
• Budde LE, Zhang MM, Shustov AR, A phase I study of vorinostat (V) in combination with rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) for patients with relapsed or refractory lymphoid malignancies or untreated T- or mantle cell lymphoma. Blood 2009;114: abstract 3696
   Web of Science ®Google Scholar
• Hess G, Smith SM, Berkenblit A, Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Oncol 2009;36(Suppl 3):S37-45
   PubMedGoogle Scholar
• Witzig T, Habermann T, Reeder C, A phase II trial of the oral mTOR inhibitor everolimus in relapsed non-Hodgkin lymphoma (NHL) and Hodgkin disease (HD). Haematologica 2009;94(Suppl 2): abstract 1081
   Google Scholar
• Pettengell R, Bertrand C, Geetha N, Phase III trial of pixantrone dimaleate compared with other agents as third-line, single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma (EXTEND): results from the treatment and follow-up periods. Blood 2009;114: abstract 1677
   Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, Inhibition of Syk with fostamatinib disodium has significant clinical activity in non Hodgkin's lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-85
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Kahl BS, Vose JM, Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-6
   PubMed Web of Science ®Google Scholar
• Cheson BD, Vose JM, Bartlett NL, Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 2009;27(Suppl): abstract 8502
   Google Scholar
• Craig M, Shah S, Tallman M, A phase II trial of darinaparsin in advanced lymphomas: report on safety and activity. Blood 2008;112: abstract 1562
   Web of Science ®Google Scholar
• Morschhauser F, Leonard JP, Fayad L, Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol 2009;27:3346-53
   PubMed Web of Science ®Google Scholar
• Micallef IN, Kahl BS, Maurer MJ, A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer 2006;107:2826-32
   PubMed Web of Science ®Google Scholar
• Micallef IN, Maurer MJ, Nikcevich DA, Final results of NCCTG N0489: epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. J Clin Oncol 2009;27(Suppl): abstract 8508
   Google Scholar
• Fayad L, Patel H, Verhoef G, Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: preliminary report of a phase 1/2 study. Blood 2008;112: abstract 266
   PubMed Web of Science ®Google Scholar
• Advani R, Forero-Torres A, Furman RR, Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4371-7
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Weaver R, Alkuzweny B, Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:4711-16
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23
   PubMed Web of Science ®Google Scholar
• Hochster H, Weller E, Gascoyne RD, Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009;27:1607-14
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-8
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StIL (Study Group Indolent Lymphomas, Germany). Blood 2009;114: abstract 405
   Web of Science ®Google Scholar
• Morschhauser F, Radford J, Van Hoof A, Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-64
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Gadeberg O, Johnson P, First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008;111:5486-95
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiernik PH, Moore T, Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 2009;27:5404-9
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Portlock C, Moskowitz C, Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res 2010;16:719-26
   PubMed Web of Science ®Google Scholar
• de Vos S, Goy A, Dakhil SR, Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 2009;27:5023-30
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Marlton P, Vitolo U, Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 2010;21:1870-6
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Vose JM, Kahl BS, A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics. Blood 2009;114: abstract 3742
   Web of Science ®Google Scholar
• Salles GA, Morschhauser F, Cartron G, A phase I/II study of Ro5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease. Blood 2008;112: abstract 234
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas JC, Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3051-9
   PubMed Web of Science ®Google Scholar
• Leonard JP, Schuster SJ, Emmanouilides C, Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008;113:2714-23
   PubMed Web of Science ®Google Scholar
• Leonard JP, Friedberg JW, Younes A, A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;18:1216-23
   PubMed Web of Science ®Google Scholar
• Kraeber-Bodere F, Morschhauser F, Huglo D, Fractionated radioimmunotherapy in NHL with DOTA-conjugated, humanized anti-CD22 IgG, epratuzumab: results at high cumulative doses of 90Y. J Clin Oncol 2008; 26:abstract 8502
   Google Scholar
• Wilson WH, O'Connor OA, Czuczman MS, Phase 1/2a study of ABT-263 in relapsed or refractory lymphoid malignancies. Blood 2009;114: abstract 1711
   Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-7
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G, Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885-91
   PubMed Web of Science ®Google Scholar
• Flinn IW, Neuberg DS, Grever MR, Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007;25:793-8
   PubMed Web of Science ®Google Scholar
• Byrd JC, Rai K, Peterson BL, Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53
   PubMed Web of Science ®Google Scholar
• Hallek M, Fingerle-Rowson G, Fink A-M, First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood 2009;114: abstract 535
   Web of Science ®Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A, Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378-84
   PubMed Web of Science ®Google Scholar
• Osterborg A. Ofatumumab, a human anti-CD20 monoclonal antibody. Expert Opin Biol Ther 2010;10:439-49
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Musial L, Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343-9
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette EJ, Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-7
   PubMed Web of Science ®Google Scholar
• Faderl S, Rai K, Gribben J, Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 2006;107:916-24
   PubMed Web of Science ®Google Scholar
• Andritsos L, Furman RR, Flinn IW, A phase 1 trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIPTM) protein in relapsed and refractory CLL: early promising clinical activity. Blood 2009;114: abstract 3424
   Web of Science ®Google Scholar
• Byrd JC, Kipps TJ, Flinn IW, Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;115:489-95
   PubMed Web of Science ®Google Scholar
• Berkova Z, Tao RH, Samaniego F. Milatuzumab – a promising new immunotherapeutic agent. Expert Opin Investig Drugs 2010;19:141-9
   PubMed Web of Science ®Google Scholar
• Lin TS, Ruppert AS, Johnson AJ, Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009;27:6012-18
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Brown JR, An ongoing phase 1/2a study of ABT-263; pharmacokinetics (PK), safety and anti-tumor activity in patients (pts) with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 2009;114: abstract 883
   Web of Science ®Google Scholar
• Flinn IW, Byrd JC, Furman RR, Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110delta Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies. Blood 2009;114: abstract 922
   Web of Science ®Google Scholar
• Shanafelt TD, Kaufmann SH, Call TG, A phase 1 trial of daily oral green tea extract in asymptomatic, Rai stage 0–II patients with chronic lymphocytic leukemia. Blood 2007;110: abstract 2047
   Google Scholar
• Geisler CH, Kolstad A, Laurell A, Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-93
   PubMed Web of Science ®Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-74
   PubMed Web of Science ®Google Scholar
• Habermann TM, Lossos IS, Justice G, Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145:344-9
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang L, Fayad L, Lenalidomide and rituximab are a promising combination in vitro, in vivo preclinically and in a phase I/II clinical trial in relapsed/refractory mantle cell lymphoma. Blood 2008;112: abstract 3058
   Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822-9
   PubMed Web of Science ®Google Scholar
• Robinson KS, Williams ME, van der Jagt RH, Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473-9
   PubMed Web of Science ®Google Scholar
• Wang M, Oki Y, Pro B, Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:5213-18
   PubMed Web of Science ®Google Scholar
• Gopal AK, Rajendran JG, Petersdorf SH, High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002;99:3158-62
   PubMed Web of Science ®Google Scholar
• Treon SP, Hatjiharissi E, Leleu X, Novel agents in the treatment of Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2007;(Suppl 5):S199-206
   Google Scholar
• Ghobrial IM, Hong F, Padmanabhan S, Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1422-8
   PubMed Web of Science ®Google Scholar
• Gertz MA, Rue M, Blood E, Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45:2047-55
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008;112(12):4452-7
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009;15:355-60
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Gertz M, Laplant B, Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1408-14
   PubMed Web of Science ®Google Scholar